Cell therapy weekly: autologous cell therapy approach improves outcomes in heart failure

This week: a clinical trial has shown for the first time that an autologous cell therapy approach for heart failure could result in improved quality of life and reduced major adverse cardiac events, Biogen announces that their experimental gene therapy did not meet its primary endpoint and did not demonstrate efficacy on key secondary endpoints for choroideremia, and Inceptor Bio are developing a next-generation CAR-T, CAR-M and NK/NKT platform to advance cell and gene therapy for difficult-to-treat cancers. The news highlights: Autologous cell therapy approach improves outcomes in heart failure Biogen’s experimental gene therapy fails to meet study endpoints Next-generation...